Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | BHMT | Q93088 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL996039 | 1.00 | KMT2A (0.37) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| SCHEMBL6259101 | 1.00 | KMT2A (0.37) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| Hydrochloric Acid SCHEMBL4678546 | 0.98 | KMT2A (0.36) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| Ammonia Solution, Strong SCHEMBL7204814 | 0.98 | TDP1 (0.39) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| Hydrochloric Acid SCHEMBL30466615 | 0.98 | KMT2A (0.36) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| Hydrochloric Acid SCHEMBL4678540 | 0.98 | KMT2A (0.36) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| SCHEMBL28364770 | 0.90 | KIF11 (0.33) | KMT2ASMN1; SMN2KIF11BHMTSLC1A1 | |
| SCHEMBL8894673 | 0.82 | SMN1; SMN2 (0.42) | SMN1; SMN2KIF11SLC1A1GFPT1 | |
| SCHEMBL29069491 | 0.81 | BHMT (0.35) | KMT2ASMN1; SMN2BHMTSLC1A1S1PR1 | |
| SCHEMBL16775768 | 0.81 | ALDH1A1 (0.40) | KMT2ASMN1; SMN2KIF11SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 633 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122068110-A | Amino acid type supermolecule gel polymer electrolyte and preparation method and application thereof | 四川荣创新能动力系统有限公司 | 2026-05-19 | — | — | CN | claimed |
| EP-3967714-B1 | VINYL ALCOHOL-AMINO ACID ESTER COPOLYMER, THEIR PREPARATION AND USES | SEKISUI CHEMICAL CO LTD (JP) | 2026-01-07 | — | — | EP | claimed |
| CN-119470406-A | Phthalic dicarboxaldehyde disinfectant concentration detection test paper and preparation method thereof | 山东新华莎罗雅生物技术有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119136613-A | Preparation method of perovskite solar cell based on buried bottom modification | 浙大宁波理工学院 | 2024-12-13 | — | — | CN | claimed |
| US-20240261422-A1 | ANTHRACYCLINE ANTIBODY CONJUGATES | SEAGEN INC (US) | 2024-08-08 | — | — | US | claimed |
| CN-118078747-A | Dry suspension of crude drug powder and its preparation method | 江苏神猴医药研究有限公司 | 2024-05-28 | — | — | CN | claimed |
| US-20240123079-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC. | 2024-04-18 | — | — | US | claimed |
| EP-4346906-A1 | ANTHRACYCLINE ANTIBODY CONJUGATES | Seagen Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| US-11905527-B2 | Gel composition for culturing cells, production method thereof, method for culturing cells, and substrate for culturing cells | SHIMADZU CORPORATION (JP) | 2024-02-20 | — | — | US | claimed |
| CN-117580593-A | Anthracycline antibody conjugates | 思进公司 | 2024-02-20 | — | — | CN | claimed |
| US-20040063771-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2004-04-01 | — | — | US | claimed |
| US-20030190258-A1 | Ophthalmic and contact lens solutions using low molecular weight amines | FXS VENTURES, LLC | 2003-10-09 | — | — | US | claimed |
| US-6569882-B2 | Viricides; enzyme inhibitors | G. D. SEARLE & CO. | 2003-05-27 | — | — | US | claimed |
| US-20030013751-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-01-16 | — | — | US | claimed |
| US-6384036-B1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE & CO. | 2002-05-07 | — | — | US | claimed |
| US-6143747-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 2000-11-07 | — | — | US | claimed |
| EP-0804428-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | claimed |
| WO-1996022287-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | claimed |
| US-4892820-A | Solvent system for enzymatic coupling process | THE NUTRASWEET COMPANY (US) | 1990-01-09 | — | — | US | claimed |
| US-3936469-A | Process for preparing N-carboxylic anhydrides of amino acids | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JA) | 1976-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123079-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | CD47, CD22, FCGR2A | KMT2A 568/4885SMN1; SMN2 2416/4885KIF11 3158/4885 |
| US-20030013751-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | DNPEP, PRSS1, PREP | KMT2A 873/4885SMN1; SMN2 2504/4885KIF11 4681/4885 |
| US-20040063771-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | DNPEP, PRSS1, PREP | KMT2A 873/4885SMN1; SMN2 2504/4885KIF11 4681/4885 |
| US-20030190258-A1 | Ophthalmic and contact lens solutions using low molecular weight amines | H1-0, ARGLU1, H1-3 | KMT2A 2111/4885SMN1; SMN2 3933/4885KIF11 372/4885 |
| US-20240261422-A1 | ANTHRACYCLINE ANTIBODY CONJUGATES | BCR, TOP2A, ABCB1 | KMT2A 707/4885SMN1; SMN2 2460/4885KIF11 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.